Skip to main content

GOLDMAN SACHS GROUP INC

Position in APLS — Apellis Pharmaceuticals, Inc.

CIK 886982 NEW YORK, NY

Position in APLS

as of Mar 31, 2026 · filed May 15, 2026
Position Value
$0
+$0 QoQ
Shares Held
1,980,144
+946.6% QoQ
Ownership
1.55%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
not a current holder
Holding Since
Mar 2020
25 quarters on record
Voting authority Sole 96% Shared 0% None 4%

Common Shares in APLS Over Time

Shares Held

Position Value (USD)

Derivatives in APLS

reported options exposure · as of Jun 30, 2025
CallValue
$0
CallShares
21,000
PutValue
$0
PutShares
21,000

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

GOLDMAN SACHS GROUP INC holds $13,040,376,854 across 359 Biotechnology names.

# Ticker Company Shares Value (USD) Open

All Filings in APLS

Export CSV
35 filing rows on record
Report Date Value (USD) Shares
2026-03-31 1,980,144
2025-12-31 189,205
2025-09-30 124,373
2025-06-30 215,999
2025-06-30 21,000
2025-06-30 21,000
2025-03-31 307,709
2024-12-31 242,967
2024-09-30 195,066
2024-06-30 146,926
2024-03-31 319,476
2023-12-31 310,583
2023-09-30 331,793
2023-09-30 20,000
2023-06-30 23,400
2023-06-30 634,897
2023-06-30 23,400
2023-03-31 663,195
2022-12-31 15,000
2022-12-31 1,061,703
2022-09-30 957,678
2022-06-30 810,399
2022-03-31 500,254
2021-12-31 498,082
2021-09-30 1,023,170
2021-06-30 694,040
2021-03-31 1,123,741
2020-12-31 1,089,531
2020-09-30 10,000
2020-09-30 1,331,610
2020-06-30 22,500
2020-06-30 1,013,060
2020-03-31 20,000
2020-03-31 29,900
2020-03-31 634,717